Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Advances in Therapy|August 6, 2025
Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician's Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple MyelomaCyrille Touzeau, Brea Lipe, Abdullah M Khan, et al.
Ejhaem|July 18, 2022
Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myelomaCristina Gasparetto, Suzanne Lentzsch, Gary Schiller, et al.
Advances in Therapy|May 12, 2025
Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect ComparisonNoemi Puig, Joris Diels, Suzy van Sanden, et al.
Ejhaem|December 5, 2022
Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatmentMuhamed Baljevic, Cristina Gasparetto, Gary J Schiller, et al.
British Journal of Cancer|November 21, 2021
Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patientsCristina Gasparetto, Gary J Schiller, Sascha A Tuchman, et al.
Leukemia|January 14, 2022
Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myelomaJohannes M Waldschmidt, Andrew J Yee, Tushara Vijaykumar, et al.
The Lancet. Haematology|March 16, 2025
Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 studyAjai Chari, Cyrille Touzeau, Carolina Schinke, et al.
The Lancet. Haematology|February 3, 2022
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working GroupNoopur S Raje, Elias Anaissie, Shaji K Kumar, et al.
Pageof 3